Welcome to our dedicated page for AION THERAPEUTIC news (Ticker: ANTCF), a resource for investors and traders seeking the latest updates and insights on AION THERAPEUTIC stock.
Aion Therapeutic Inc. (CSE: AION) is a progressive health and wellness company with a diverse intellectual property portfolio. The company has made significant strides by acquiring Toppen Health Inc., a US-based innovative company dedicated to delivering cutting-edge water filtration solutions. Toppen's flagship product, the UltraSafe series, is a three-stage water filtration system designed to remove an extensive range of contaminants, including bacteria, viruses, pharmaceuticals, heavy metals, and PFAS. The company's recent patented Center Core technology aims to revolutionize water filtration processes, especially in industries like healthcare and dental, by providing maximum filter flexibility and eliminating the need for extensive and costly testing. With a commitment to innovation, affordability, and sustainability, Aion Therapeutic and Toppen Health are positioned to drive positive change and redefine health and wellness boundaries globally.
Aion Therapeutic (CSE: AION) provides a bi-weekly update regarding its management cease trade order (MCTO) issued by the British Columbia Securities Commission on August 29, 2024. The company has delayed filing its annual financial statements for the year ended April 30, 2024, and subsequent interim financial statements for the period ended July 31, 2024. The delay is attributed to complexities in the accounting process following the acquisition of Toppen Health, Inc. on December 15, 2023. The BCSC has extended the filing deadline to October 28, 2024, which the company expects to meet. The interim filings are expected to be completed within five business days after the annual filings.
Aion Therapeutic (CSE: AION) has appointed Charles Freihofer as Chief Revenue Officer (CRO) of its water filtration subsidiary, Toppen Health. Freihofer, who joined in mid-September, brings over 20 years of experience in sales, marketing, and operations. In his previous role as President and CRO at Nvatomate, he achieved triple revenue growth and increased profit margins fivefold. The company also announced Larry Horwitz's resignation as director effective October 18, 2024, leaving the board with four directors.
Aion Therapeutic Inc. (CSE: AION) has provided a bi-weekly update on its management cease trade order (MCTO) issued on August 29, 2024, by the British Columbia Securities Commission. The company is unable to file its annual and interim financial statements due to complexities associated with the acquisition of Toppen Health, Inc. on December 15, 2023. The BCSC has extended the deadline for Annual Filings to October 28, 2024, which the company expects to meet. Aion Therapeutic confirms there are no material changes to the information in the Default Announcement and is complying with the Alternative Information Guidelines set out in NP 12-203.
Aion Therapeutic Inc. (CSE: AION), through its subsidiary Toppen Health, has donated multiple water filtration systems to Trinity Baptist Church to support Hurricane Helene recovery efforts in western North Carolina. The hurricane has left communities devastated, with over 160 boil water advisories in effect and 27 water plants closed. Toppen's filters, made in the USA, can reduce bacteria by 99.9999999%, viruses by 99.9999%, and remove PFAS, micro-plastics, pesticides, and pharmaceuticals.
Toppen offers whole-home or business filtration solutions, as well as personal filtration straws and water bottles. The company's CEO, Owen Boyd, emphasized the importance of helping neighboring communities access clean water. For more information on Toppen's products or to support recovery efforts in western North Carolina, interested parties can contact Toppen Health or visit Trinity Baptist Church's website.
Aion Therapeutic Inc. (CSE: AION) has announced that its water filtration subsidiary, Toppen Health, Inc., has received Canadian Standards Association (CSA) Group certification for certain models of its water filtration solutions. The certification, granted on September 26, 2024, is for Class 6811 43 PLUMBING - DRINKING WATER TREATMENT SYSTEMS, certified to CSA B483.1.
Toppen's UltraSafe series of water filters with proprietary MicronGuard™ technology have met CSA's safety and performance requirements for Canada. The UltraSafe system is designed to eliminate 99.99% of bacteria, pathogens, PFAS, pharmaceuticals, and microplastics in drinking water while retaining essential nutrients and minerals. The filters can be installed at a water source's point of entry or via source-specific options like under-sink installations.
Owen Boyd, CEO of Toppen, stated that this certification allows the company to enter the Canadian marketplace and provides additional consumer confidence. Toppen has already been introducing its products to potential Canadian distributors and can now begin executing distribution agreements and taking sales orders.
Aion Therapeutic Inc. (CSE: AION) has provided a bi-weekly update on its management cease trade order (MCTO) issued on August 29, 2024, by the British Columbia Securities Commission. The company is unable to file its 2024 Financial Disclosure by the August 28, 2024 deadline due to complexities associated with the acquisition of Toppen Health, Inc. on December 15, 2023. The BCSC has extended the filing deadline to October 28, 2024, which Aion Therapeutic expects to meet. The company confirms no material changes to the information in the Default Announcement and continues to satisfy the Alternative Information Guidelines set out in NP 12-203.
Aion Therapeutic Inc. (CSE: AION) has provided a bi-weekly update on its management cease trade order (MCTO) issued by the British Columbia Securities Commission on August 29, 2024. The company is unable to file its 2024 Financial Disclosure by the August 28, 2024 deadline due to complexities associated with the acquisition of Toppen Health, Inc. on December 15, 2023. The BCSC has granted an extension until October 28, 2024 for the company to complete its financial disclosure, which Aion Therapeutic expects to meet. The company confirms no material changes to the information in the Default Announcement and continues to satisfy the Alternative Information Guidelines set out in NP 12-203.
Aion Therapeutic Inc. (CSE: AION) has been granted a management cease trade order (MCTO) by the British Columbia Securities Commission, extending the deadline for filing its 2024 Financial Disclosure to October 28, 2024. The delay is due to the recent acquisition of Toppen Health, Inc., which requires additional valuations and impairment testing. The MCTO prohibits the CEO and CFO from trading company securities until the filing is complete. Aion Therapeutic is working to finalize the disclosure as quickly as possible and will issue bi-weekly status updates. The company confirms no insolvency proceedings and no undisclosed material information.
Aion Therapeutic Inc. (CSE: AION) has announced a delay in filing its 2024 annual financial statements due by August 28, 2024. The delay is attributed to the recent acquisition of Toppen Health, Inc. on December 15, 2023, which requires additional valuations and impairment testing. The company expects to file the 2024 Financial Disclosure by the end of September 2024.
As a result, Aion Therapeutic has applied for a management cease trade order (MCTO) effective August 14, 2024, preventing management from trading company securities until the documentation is filed. The company will adhere to the Alternative Information Guidelines outlined in National Policy 12-203 during this period.
Aion Therapeutic Inc. (CSE: AION) has secured a worldwide licensing agreement for I2Pure Corp.'s patented molecular iodine technology for water disinfection applications. This agreement enhances Toppen Health's advanced water filtration systems, allowing for the removal of pathogens, PFAS, and pharmaceuticals from any water source. The license includes:
1. A four-year exclusive worldwide license
2. A cash payment of USD $250,000
3. USD $1,000,000 in Aion Therapeutic common shares
4. A 6% royalty fee on transactions using I2Pure's technologies, starting one year after the agreement
The agreement aims to revolutionize water filtration and disinfection, particularly in dental and healthcare industries, by combining Toppen's advanced filtration with I2Pure's molecular iodine technology.
FAQ
What is the current stock price of AION THERAPEUTIC (ANTCF)?
What is the market cap of AION THERAPEUTIC (ANTCF)?
What is Aion Therapeutic Inc.'s core business?
What is Toppen Health Inc. known for?
What is the significance of the Center Core technology?
How does Toppen Health's filtration system work?
What is the recent achievement of Aion Therapeutic Inc.?
